2Parkin DM, Bray F, Ferlay Jet al. Estimating the world canc- er burden: Globocan 2000 [J]. Int J Cancer, 2001, 94 (2) : 153.
3Future Ⅱ Study Group. Quadrivalent vaccine against human papillomavirus to prevent high - grade cervical lesions[J] . NEnglJMed, 2007, 356 (19): 1915.
4Jemal A, Bray F, Center MM, et al. Global cancer statistics[J] . CA Cancer J Clin, 2011, 61 (2) : 69.
5Forman D, de Martel C, Lacey C J, et al. Global burden of human papillomavirus and related diseases [ J . Vaccine, 2012, 30 (5): 12.
6Li J, Kang LN, Qiao YL. Review of the cervical cancer dis- ease burden in China's Mainland [ J] . Asian Pac J Cancer Prey, 2011, 12 (5): 1149.
7Patel A, Galaal K, Burnley C, et al. Cervical cancer inci- dence in young women: a historical and geographic controlled UK regional population study [ J] . Br J Cancer, 2012, 106 (11): 1753.
8Goldstone SE, Vuocolo S. A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV -6, -11, -16and -18 [J] .ExpertRevVaccines, 2012, 11 (4) : 395.
9Mc Corrnack PL, Joura EA. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18)recombinant vaccine (Gardasil?) in the prevention of prernalignant genital lesions, genital cancer, and genital warts in women [J] . Biol Drugs, 2011, 25 (5): 339.
